WebDoctor Encyclopedia

Lung Soft-tissue sarcomas

Intimal sarcoma

Intimal sarcoma is a very rare sarcoma growing from the inner lining of large arteries, most often the pulmonary artery. It is frequently mistaken for a blood clot, carries MDM2 gene amplification, and is treated with surgery, chemotherapy and radiotherapy.

Medically reviewed Last reviewed November 15, 2026

What is intimal sarcoma?

Intimal sarcoma is a very rare cancer that grows from the inner lining of large blood vessels. This lining is called the intima, which gives the tumour its name.

The tumour most often starts in the pulmonary artery, the large vessel that carries blood from the heart to the lungs. It can also arise in the aorta, the main artery of the body, and in the heart, where similar tumours are often called undifferentiated cardiac sarcomas.

Because it grows inside the vessel, intimal sarcoma behaves like a blood clot. It narrows or blocks the artery and is very often mistaken for a pulmonary embolism at first. Many people receive blood-thinning treatment for months before the true cause is found (Assi, Kattan and Rassy, 2020).

Most intimal sarcomas carry extra copies of the MDM2 gene, a change that helps pathologists confirm the diagnosis and that new medicines are trying to target (Koelsche et al., 2021). Treatment usually combines major surgery with chemotherapy and sometimes radiotherapy, but the outlook is serious.

1. Key facts at a glance

Feature Details
Type of cancer Sarcoma arising from the inner lining of large arteries or the heart
How common Extremely rare; only a few hundred cases of pulmonary artery sarcoma have been described in detail
Typical age Adults; average about 45-55 years
Sex Men and women affected about equally, with a slight female excess in some reports
Main sites Pulmonary trunk and main pulmonary arteries; aorta; left atrium of the heart
Key gene change MDM2 amplification, often with CDK4 and PDGFRA
Common mix-up Pulmonary embolism or chronic thromboembolic disease
Main treatment Surgery, chemotherapy, radiotherapy
Outlook Serious; best when the tumour can be removed completely

2. Where intimal sarcoma grows

Site Notes
Pulmonary artery The most common site; usually starts in the main trunk and spreads along the branches
Pulmonary valve and right ventricle Tumour may grow backwards into the heart
Aorta Usually the descending thoracic or abdominal aorta; may cause blockages downstream
Heart (left atrium) Tumours here share the same MDM2 gene change and are now regarded as closely related
Other large arteries Very rarely, the iliac or femoral arteries

3. Causes and risk factors

The cause of intimal sarcoma is not known. No link with smoking, diet, lifestyle, previous clots or blood thinners has been found.

Gene changes

Gene change Frequency Notes
MDM2 amplification Most cases Switches off the p53 protective pathway; the key diagnostic marker
CDK4 amplification Many cases Promotes cell division
PDGFRA amplification or activation Many cases A growth-signalling gene; a possible drug target
EGFR amplification Some cases Another growth-signalling gene
MDM4 or CDK6 amplification A small number, usually without MDM2 gain Described in heart and vessel sarcomas (Koelsche et al., 2021)

These changes are acquired in the tumour cells. They are not inherited and do not pass to children.

4. How does it look

On scans

Intimal sarcoma usually looks like a filling defect inside the artery, which is why it is often confused with a clot.

Feature What it suggests
Defect that fills the whole width of the artery Sometimes called the wall-eclipsing sign; favours tumour over clot
Spread backwards towards the heart or valve Unusual for a clot
Lobulated, bulging edge Favours tumour
Enhancement after contrast on CT or MRI Shows the mass has a blood supply, unlike a clot
High uptake on PET-CT Suggests an active tumour
Growth through the vessel wall Indicates invasion of nearby tissue
No improvement on blood thinners A strong clue that the defect is not a clot

During surgery

Feature Description
Shape A polypoid or sausage-like mass growing along the inside of the artery
Colour Grey, white or yellowish, often mixed with real clot
Consistency Soft and jelly-like to firm and rubbery
Attachment Firmly stuck to the vessel wall at its base

Under the microscope

Feature Description
Cells Spindle-shaped or rounded cells with very abnormal nuclei
Pattern Usually undifferentiated; sometimes areas of bone, cartilage or muscle-like tissue
Background Myxoid (jelly-like) areas and clot are common
Stains MDM2 nuclear staining in most cases; CDK4 often positive
Molecular test FISH or sequencing shows MDM2 amplification

5. Symptoms

Symptoms are caused by blockage of blood flow and depend on which vessel is involved. They usually develop gradually over weeks or months.

Pulmonary artery sarcoma

Symptom Notes
Breathlessness The most common symptom, slowly worsening
Chest pain Often dull or pressing
Cough Sometimes with blood (haemoptysis)
Tiredness and reduced exercise capacity From strain on the right side of the heart
Ankle swelling and fainting Signs of right heart failure
Fever, night sweats and weight loss General symptoms seen in some people
Palpitations Uneven heartbeat

Aortic sarcoma

  • Pain in the legs when walking, cold limbs or numbness, from blockage or small clots travelling downstream
  • Sudden tummy pain if bowel arteries are blocked
  • Back pain or a pulsating lump if the aorta swells
  • High blood pressure if the kidney arteries are affected

Heart (left atrial) sarcoma

  • Breathlessness, especially lying flat
  • Palpitations
  • Stroke-like symptoms if fragments travel to the brain

Clues that a “clot” might be a tumour

  • Symptoms keep getting worse despite proper blood-thinning treatment
  • There is no obvious cause for a clot, such as a leg vein thrombosis
  • The person has fever, weight loss or a high ESR or CRP
  • Scans show a bulging mass extending into the heart or through the vessel wall

When to seek medical advice

Seek urgent care for sudden breathlessness, chest pain, fainting or coughing blood. If you have been treated for a pulmonary embolism and are not improving, ask your doctor whether further imaging is needed.

6. Diagnosis

Test Purpose
CT pulmonary angiogram Usually the first test; shows a filling defect
Cardiac MRI with contrast Helps separate tumour from clot
PET-CT Shows active tumour and looks for spread
Echocardiogram Assesses the heart valves and the pressure in the lungs
Biopsy Taken through a catheter inside the vessel, by needle, or during surgery
MDM2 testing Immunohistochemistry and FISH confirm the diagnosis
Staging scans CT of chest, abdomen and pelvis, sometimes brain imaging

Getting tissue from inside the pulmonary artery can be difficult. In many people the diagnosis is made only at surgery for presumed chronic clots (Assi, Kattan and Rassy, 2020).

Conditions that can look similar

Condition How it differs
Acute pulmonary embolism Sudden onset; improves with blood thinners
Chronic thromboembolic pulmonary hypertension Thin webs and narrowing rather than a bulging mass
Other sarcomas spreading into vessels A main tumour is found elsewhere
Cardiac myxoma Benign heart tumour; different appearance and no MDM2 gain

Why diagnosis is often delayed

Studies of pulmonary artery sarcoma show that the right diagnosis is frequently made several months after the first symptoms. There are a few reasons for this:

  • Pulmonary embolism is thousands of times more common, so doctors reasonably treat it first
  • The tumour often contains real clot on its surface, which hides the mass beneath
  • Standard CT scans show only a dark shape inside the artery, without telling what it is made of
  • The symptoms, such as breathlessness and tiredness, are common and non-specific

Specialist pulmonary hypertension centres now look carefully for tumour features in anyone with unexplained or worsening clots in the main pulmonary arteries.

7. Treatment

Treatment should take place in a specialist centre with cardiothoracic surgeons, sarcoma oncologists and radiologists experienced in this tumour.

Surgery

Operation Notes
Pulmonary endarterectomy Tumour is cleared from inside the arteries; restores blood flow and relieves symptoms
Resection of the artery with graft Removes the involved vessel segment and replaces it
Removal of part or all of a lung If the tumour extends into the lung
Valve replacement If the pulmonary valve is involved
Aortic resection and graft For aortic tumours
Removal of heart tumour For left atrial disease, sometimes with heart reconstruction

Surgery provides the best chance of long-term control, but complete removal is often not possible because the tumour spreads along the vessel.

Chemotherapy

Situation Usual drugs
Before or after surgery Doxorubicin, often with ifosfamide
Advanced disease Doxorubicin-based treatment first; gemcitabine and docetaxel later
Clinical trials MDM2 inhibitors, CDK4/6 inhibitors and PDGFRA-targeted drugs are being studied (López Subires, Amondarain Amenabar and Valverde, 2026)

Radiotherapy

Radiotherapy may be given after surgery to reduce the chance of the tumour returning, or to relieve symptoms when surgery is not possible.

Side effects

Treatment Possible side effects
Heart and lung surgery Bleeding, infection, irregular heartbeat, long recovery
Chemotherapy Hair loss, sickness, tiredness, low blood counts, heart strain (doxorubicin), kidney and bladder effects (ifosfamide)
Radiotherapy Tiredness, inflammation of the lungs or oesophagus

What treatment involves day to day

Part of treatment What to expect
Major heart-lung surgery Several days in intensive care and 1-3 weeks in hospital
Recovery at home Usually 2-3 months before normal activity returns
Chemotherapy Hospital visits every 3 weeks, sometimes with overnight stays for ifosfamide
Radiotherapy Short daily sessions on weekdays for several weeks

8. Outlook (prognosis)

Situation Approximate outlook
No surgery Often a matter of months, typically under 1-1.5 years
Surgery with complete removal Median survival can reach about 3 years, with some long-term survivors
Surgery plus chemotherapy or radiotherapy Several series suggest better results than surgery alone
Spread to other organs Lungs, bone, brain and kidneys; outlook usually poor

Figures come from small series and vary widely (Assi, Kattan and Rassy, 2020). Early diagnosis, before the tumour has grown far along the vessels, is the most important factor for a better result.

9. Follow-up

Follow-up Purpose
CT or MRI every 3 months at first Detects regrowth inside the vessels or new spread
Echocardiogram Checks heart function and lung pressures
PET-CT When scans are unclear
Heart monitoring during chemotherapy Especially with doxorubicin

10. Living with intimal sarcoma

  • Pace yourself, as breathlessness and tiredness are common during recovery
  • Ask for cardiac or pulmonary rehabilitation after major surgery
  • Report worsening breathlessness, chest pain or swelling promptly
  • Keep an up-to-date list of medicines, including blood thinners, and carry it with you
  • Ask about clinical trials, as research is active in MDM2-driven sarcomas
  • Seek emotional support from sarcoma charities and specialist nurses

11. Frequently asked questions

Question Answer
Is intimal sarcoma a type of blood clot? No. It is a cancer, but it can cause clots and look like one on scans
Why was I first treated for a pulmonary embolism? The two look very similar on standard CT scans, and embolism is far more common
Is it inherited? No
Can it be cured? A minority of people remain well for years after complete surgery
Does it spread? Yes, mainly along the arteries and to the lungs, but also to other organs
Are there targeted treatments? Drugs aimed at MDM2 and CDK4 are being tested in trials

12. Questions to ask your care team

  • How sure are you that this is a tumour rather than a clot?
  • Has the tumour been tested for MDM2 and other gene changes?
  • Can it be removed with surgery, and what does the operation involve?
  • Should I have chemotherapy before or after surgery?
  • Am I eligible for a clinical trial?
  • What symptoms should make me contact the team urgently?

Resources

  1. Assi, T., Kattan, J. and Rassy, E. (2020) ‘A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery’, Critical Reviews in Oncology/Hematology, 147, 102889.
  2. Giner, F. et al. (2023) ‘Intimal sarcoma with MDM2/CDK4 amplification and p16 overexpression: a review of histological features in primary tumor and xenograft, with immunophenotype and molecular profiling’, International Journal of Molecular Sciences, 24(8), 7535.
  3. Koelsche, C. et al. (2021) ‘Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature’, Modern Pathology, 34(12), pp. 2122-2129.
  4. Lefler, D.S. et al. (2025) ‘Sarcoma: cardiovascular and oncologic considerations: JACC: CardioOncology state-of-the-art review’, JACC: CardioOncology, 7(7), pp. 800-815.
  5. López Subires, S., Amondarain Amenabar, N. and Valverde, C. (2026) ‘Intimal sarcoma, review and future perspectives’, Current Opinion in Oncology, 38(4), pp. 310-318.
  6. Qin, J. et al. (2021) ‘Pulmonary artery intimal sarcoma – a primeval or rediscovered tumor? A report of 14 new cases with literature review’, Pathology, Research and Practice, 224, 153548.
  7. National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.